Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Zuzana Nahacka, Renata Zobalova, Maria Dubisova, Jakub Rohlena & Jiri Neuzil. (2021) Miro proteins connect mitochondrial function and intercellular transport. Critical Reviews in Biochemistry and Molecular Biology 56:4, pages 401-425.
Read now
Read now
Weiqiang Guo, Bin Xu, Xiaoxiao Wang, Bo Zheng, Jiahui Du & Songbai Liu. (2020) The Analysis of the Anti-Tumor Mechanism of Ursolic Acid Using Connectively Map Approach in Breast Cancer Cells Line MCF-7. Cancer Management and Research 12, pages 3469-3476.
Read now
Read now
Hao Mo, Juliang He, Zhenchao Yuan, Zhenjie Wu, Bin Liu, Xiang Lin & Jian Guan. (2019) PLK1 contributes to autophagy by regulating MYC stabilization in osteosarcoma cells. OncoTargets and Therapy 12, pages 7527-7536.
Read now
Read now
Judith Lind, Felix Czernilofsky, Sonia Vallet & Klaus Podar. (2019) Emerging protein kinase inhibitors for the treatment of multiple myeloma. Expert Opinion on Emerging Drugs 24:3, pages 133-152.
Read now
Read now
Stefanie Ruf, Alexander Martin Heberle, Miriam Langelaar-Makkinje, Sara Gelino, Deepti Wilkinson, Carolin Gerbeth, Jennifer Jasmin Schwarz, Birgit Holzwarth, Bettina Warscheid, Chris Meisinger, Marcel A. T. M. van Vugt, Ralf Baumeister, Malene Hansen & Kathrin Thedieck. (2017) PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy. Autophagy 13:3, pages 486-505.
Read now
Read now
Articles from other publishers (32)
Katyna Sada Del Real & Angel Rubio. (2023) Discovering the mechanism of action of drugs with a sparse explainable network. eBioMedicine 95, pages 104767.
Crossref
Crossref
Danda Chapagai, George Merhej, Campbell McInnes & Michael D. Wyatt. (2023) Structural Basis for Variations in Polo-like Kinase 1 Conformation and Intracellular Stability Induced by ATP-Competitive and Novel Noncompetitive Abbapolin Inhibitors. ACS Chemical Biology 18:7, pages 1642-1652.
Crossref
Crossref
Jung-Eun Park, Hobin Lee, Paola Oliva, Klara Kirsch, Bora Kim, Jong Il Ahn, Celeste N. Alverez, Snehal Gaikwad, Kristopher W. Krausz, Robert O’Connor, Ganesha Rai, Anton Simeonov, Beverly A. Mock, Frank J. Gonzalez, Kyung S. Lee & Kenneth A. Jacobson. (2023) Structural Optimization and Anticancer Activity of Polo-like Kinase 1 (Plk1) Polo-Box Domain (PBD) Inhibitors and Their Prodrugs. ACS Pharmacology & Translational Science 6:3, pages 422-446.
Crossref
Crossref
Weiguo Zhang, Guopan Yu, Hongying Zhang, Mahesh Basyal, Charlie Ly, Bin Yuan, Vivian Ruvolo, Sujan Piya, Seemana Bhattacharya, Qi Zhang, Gautam Borthakur, Venkata Battula, Marina Konopleva, William G. Rice & Michael Andreeff. (2022) Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy. Haematologica 108:6, pages 1500-1514.
Crossref
Crossref
Zuzana Nahacka, Jaromir Novak, Renata Zobalova & Jiri Neuzil. (2022) Miro proteins and their role in mitochondrial transfer in cancer and beyond. Frontiers in Cell and Developmental Biology 10.
Crossref
Crossref
Peter Mubanga Cheuka. (2022) Drug Discovery and Target Identification against Schistosomiasis: A
Reality Check on Progress and Future Prospects. Current Topics in Medicinal Chemistry 22:19, pages 1595-1610.
Crossref
Crossref
Sandra N. Craig, Merissa Baxter, Danda Chapagai, Jessy M. Stafford, Elmar Nurmemmedov, Diego Altomare, Michael D. Wyatt & Campbell McInnes. (2022) Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. European Journal of Medicinal Chemistry 227, pages 113926.
Crossref
Crossref
Yaxi Li, Hongting Wang, Zijing Zhang, Chenling Tang, Xinjin Zhou, Chandra Mohan & Tianfu Wu. (2022) Identification of polo‐like kinase 1 as a therapeutic target in murine lupus. Clinical & Translational Immunology 11:1.
Crossref
Crossref
Danda Chapagai, Gurusankar Ramamoorthy, Jessy Varghese, Elmar Nurmemmedov, Campbell McInnes & Michael D. Wyatt. (2021) Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. Journal of Medicinal Chemistry 64:14, pages 9916-9925.
Crossref
Crossref
Christopher A. Raab, Monika Raab, Sven Becker & Klaus Strebhardt. (2021) Non-mitotic functions of polo-like kinases in cancer cells. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1875:1, pages 188467.
Crossref
Crossref
Merissa Baxter, Danda Chapagai, Sandra Craig, Cecilia Hurtado, Jessy Varghese, Elmar Nurmemmedov, Michael D. Wyatt & Campbell McInnes. (2020) Peptidomimetic Polo‐Box‐Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. ChemMedChem 15:12, pages 1058-1066.
Crossref
Crossref
Xiabin Ren, Juan Liu, Li Hu, Quan Liu, Dehui Wang & Xianhui Ning. (2019) Caffeic Acid Phenethyl Ester Inhibits the Proliferation of HEp2 Cells by Regulating Stat3/Plk1 Pathway and Inducing S Phase Arrest. Biological and Pharmaceutical Bulletin 42:10, pages 1689-1693.
Crossref
Crossref
Ratnakar Singh, Shaohua Peng, Pavitra Viswanath, Vaishnavi Sambandam, Li Shen, Xiayu Rao, Bingliang Fang, Jing Wang & Faye M Johnson. (2019)
Non‐canonical
cM
et regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
. EMBO Molecular Medicine 11:5.
Crossref
Crossref
Peter J. Klauck, Stacey M. Bagby, Anna Capasso, Erica L. Bradshaw-Pierce, Heather M. Selby, Anna Spreafico, John J. Tentler, Aik Choon Tan, Jihye Kim, John J. Arcaroli, Alicia Purkey, Wells A. Messersmith, Keisuke Kuida, S. Gail Eckhardt & Todd M. Pitts. (2018) Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer 18:1.
Crossref
Crossref
Kazuhisa Ishimoto, Keiichiro Nakaoka, Osamu Yabe, Atsuko Nishiguchi & Tomomi Ikemoto. (2018) A practical chromatography-free synthesis of a 5,6-dihydroimidazolo[1,5-f]pteridine derivative as a polo-like kinase-1 inhibitor. Tetrahedron 74:39, pages 5779-5790.
Crossref
Crossref
Russell J. Pearson, David G. Blake, Mokdad Mezna, Peter M. Fischer, Nicholas J. Westwood & Campbell McInnes. (2018) The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. Cell Chemical Biology 25:9, pages 1107-1116.e4.
Crossref
Crossref
Rahul Singh, Rachel Beasley, Thavy Long & Conor R. Caffrey. (2018) Algorithmic Mapping and Characterization of the Drug-Induced Phenotypic-Response Space of Parasites Causing Schistosomiasis. IEEE/ACM Transactions on Computational Biology and Bioinformatics 15:2, pages 469-481.
Crossref
Crossref
Ming Zhang, Ratnakar Singh, Shaohua Peng, Tuhina Mazumdar, Vaishnavi Sambandam, Li Shen, Pan Tong, Lerong Li, Nene N. Kalu, Curtis R. Pickering, Mitchell Frederick, Jeffrey N. Myers, Jing Wang & Faye M. Johnson. (2017) Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Letters 392, pages 71-82.
Crossref
Crossref
Carlos Carbajales, Jun-ichi Sawada, Giovanni Marzaro, Eddy Sotelo, Luz Escalante, Antonio Sánchez-Díaz Marta, Xerardo García-Mera, Akira Asai & Alberto Coelho. (2017) Multicomponent Assembly of the Kinesin Spindle Protein Inhibitor CPUYJ039 and Analogues as Antimitotic Agents. ACS Combinatorial Science 19:3, pages 153-160.
Crossref
Crossref
Ines Lohse, Jacqueline Mason, Pinjiang Mary Cao, Melania Pintilie, Mark Bray & David W. Hedley. (2016) Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts. Oncotarget 8:2, pages 3064-3071.
Crossref
Crossref
Hanley N. Abramson. (2016) Kinase inhibitors as potential agents in the treatment of multiple myeloma. Oncotarget 7:49, pages 81926-81968.
Crossref
Crossref
Taikangxiang Yun, Tan Qin, Ying Liu & Luhua Lai. (2016) Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors. European Journal of Medicinal Chemistry 124, pages 229-236.
Crossref
Crossref
Yuehong Wang, Ratnakar Singh, Liguang Wang, Monique Nilsson, Ruchitha Goonatilake, Pan Tong, Lerong Li, Uma Giri, Pamela Villalobos, Barbara Mino, Jaime Rodriguez-Canales, Ignacio Wistuba, Jing Wang, John V. Heymach & Faye M. Johnson. (2016)
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with
T790M
mutations
. Oncotarget 7:30, pages 47998-48010.
Crossref
Crossref
Seongsoo Lee, Kyu-Sun Lee, Sungun Huh, Song Liu, Do-Yeon Lee, Seung Hyun Hong, Kweon Yu & Bingwei Lu. (2016) Polo Kinase Phosphorylates Miro to Control ER-Mitochondria Contact Sites and Mitochondrial Ca 2+ Homeostasis in Neural Stem Cell Development. Developmental Cell 37:2, pages 174-189.
Crossref
Crossref
Lilly Magdalena Weiß, Manuela Hugle, Sarah Romero & Simone Fulda. (2016) Synergistic induction of apoptosis by a polo-like kinase 1 inhibitor and microtubule-interfering drugs in Ewing sarcoma cells. International Journal of Cancer 138:2, pages 497-506.
Crossref
Crossref
C Helmke, S Becker & K Strebhardt. (2015) The role of Plk3 in oncogenesis. Oncogene 35:2, pages 135-147.
Crossref
Crossref
Thavy Long, R. Jeffrey Neitz, Rachel Beasley, Chakrapani Kalyanaraman, Brian M. Suzuki, Matthew P. Jacobson, Colette Dissous, James H. McKerrow, David H. Drewry, William J. Zuercher, Rahul Singh & Conor R. Caffrey. (2016) Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni. PLOS Neglected Tropical Diseases 10:1, pages e0004356.
Crossref
Crossref
Marianna Trakala, David Partida, María Salazar-Roa, María Maroto, Paulina Wachowicz, Guillermo de Cárcer & Marcos Malumbres. (2015) Activation of the endomitotic spindle assembly checkpoint and thrombocytopenia in Plk1-deficient mice. Blood 126:14, pages 1707-1714.
Crossref
Crossref
V Archambault, G Lépine & D Kachaner. (2015) Understanding the Polo Kinase machine. Oncogene 34:37, pages 4799-4807.
Crossref
Crossref
Lingling Duan, Ganesha Rai, Carlos Roggero, Qing-Jun Zhang, Qun Wei, Shi Hong Ma, Yunyun Zhou, John Santoyo, Elisabeth D. Martinez, Guanghua Xiao, Ganesh V. Raj, Ajit Jadhav, Anton Simeonov, David J. Maloney, Josep Rizo, Jer-Tsong Hsieh & Zhi-Ping Liu. (2015) KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes. Chemistry & Biology 22:9, pages 1185-1196.
Crossref
Crossref
Valentina Zuco, Michelandrea De Cesare, Nadia Zaffaroni, Cinzia Lanzi & Giuliana Cassinelli. (2015) PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins. Oncotarget 6:11, pages 8736-8749.
Crossref
Crossref
Joseph M. Brandwein. (2015) Targeting polo-like kinase 1 in acute myeloid leukemia. Therapeutic Advances in Hematology 6:2, pages 80-87.
Crossref
Crossref